BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34678532)

  • 41. [Clinicopathologic and molecular features of cribriform morular variant of papillary thyroid carcinoma].
    Cui XJ; Zhao HO; Su P; Chen J; Zhang RY; Pan Y; Ouyang XM; Liu J; Zhang JQ; Yang Y; Yang R; Ding L; Liu ZY
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):354-359. PubMed ID: 29783802
    [No Abstract]   [Full Text] [Related]  

  • 42. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.
    Charles RP; Iezza G; Amendola E; Dankort D; McMahon M
    Cancer Res; 2011 Jun; 71(11):3863-71. PubMed ID: 21512141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
    Paek SH; Kim BS; Kang KH; Kim HS
    World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association Between BRAF
    Shangguan R; Hu YP; Huang J; Yang SJ; Ye L; Lin RX; Zhu J; Zhang TL; Ying L; Li P
    Acad Radiol; 2019 Feb; 26(2):154-160. PubMed ID: 29941398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells.
    Lee G; Kang YE; Oh C; Liu L; Jin Y; Lim MA; Won HR; Chang JW; Koo BS
    Auris Nasus Larynx; 2020 Oct; 47(5):870-880. PubMed ID: 32381353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic clues indicating tall cell variants of papillary thyroid carcinoma in fine needle aspiration.
    Tanaka A; Hirokawa M; Higuchi M; Suzuki A; Yamao N; Hayashi T; Kuma S; Miyauchi A
    Diagn Cytopathol; 2019 May; 47(5):452-457. PubMed ID: 30582297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile.
    Lubitz CC; Economopoulos KP; Pawlak AC; Lynch K; Dias-Santagata D; Faquin WC; Sadow PM
    Thyroid; 2014 Jun; 24(6):958-65. PubMed ID: 24417340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
    Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
    Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
    Gauchotte G; Philippe C; Lacomme S; LĂ©otard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
    Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.
    Fibbi B; Pinzani P; Salvianti F; Rossi M; Petrone L; De Feo ML; Panconesi R; Vezzosi V; Bianchi S; Simontacchi G; Mangoni M; Pertici M; Forti G; Pupilli C
    Endocr Pathol; 2014 Sep; 25(3):324-31. PubMed ID: 24858900
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conventional Ultrasound, Immunohistochemical Factors and BRAF
    Chen J; Li XL; Zhao CK; Wang D; Wang Q; Li MX; Wei Q; Ji G; Xu HX
    Ultrasound Med Biol; 2018 Nov; 44(11):2296-2306. PubMed ID: 30100099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Key candidate genes associated with BRAF
    Yu X; Zhong P; Han Y; Huang Q; Wang J; Jia C; Lv Z
    J Cell Physiol; 2019 Dec; 234(12):23369-23378. PubMed ID: 31161615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SOX11 expression in a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma containing BRAF c.1799_1801delTGA and CTNNB1 c.133T>C mutations.
    Wong SBJ; Nga ME; Michal M; Vanecek T; Seet JE; Petersson F
    Virchows Arch; 2019 Oct; 475(4):519-525. PubMed ID: 31327063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.